The burden of shift-work disorder (SWD) is multifactorial—affecting relationships, health, and work performance. Lack of support, research, and treatment for SWD has economic and safety consequences for society in general. In this supplement, sleep experts suggest practical steps to relieve the adverse effects of SWD.
Shift-work disorder
Dr Culpepper reports that he serves as a consultant to AstraZeneca, Eli Lilly and Company, Pfizer Inc, Wyeth, sanofi-aventis, and Takeda Pharmaceuticals North America, Inc, and on the speakers bureau of Wyeth.
Dr Drake reports that he has received research support from Cephalon, Inc., Takeda Pharmaceuticals North America, Inc, and Zeo, Inc., and has served on the speakers bureaus of Cephalon, Inc., and as a consultant to sanofi-aventis.
Dr Schwartz reports that he serves as a consultant to and on the speakers bureaus of AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Cephalon, Inc., Pfizer Inc, Sepracor Inc., Takeda Pharmaceuticals North America, Inc, and GlaxoSmithKline.
Dr Thorpy reports that he serves as a consultant to and on the speakers bureaus of Cephalon, Inc., and Jazz Pharmaceuticals, Inc.